Congressional appropriators want more in the OTC oral contraceptive category from the US Food and Drug Administration than the first nonprescription birth control pill it approved in 2023 while also encouraging progress on OTC diagnostic tests and requesting an explanation of its homeopathic drug regulation.
The House and Senate appropriation committees recently published their reports stating instructions and requests for the FDA along with their...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?